Hong-Jian Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hong-Jian Zhu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Andrew M. Sizeland
From the Ludwig Institute for Cancer Research, Post Office, Royal Melbourne Hospital, Victoria 3050, Australia
2 shared publicationsAntony W. Burgess
The Cooperative Research Center for Cellular Growth Factors, Post Office Royal Melbourne Hospital, 3050, Victoria, Australia
2 shared publicationsJosephine Iaria
Ludwig Institute for Cancer Reaseach, Post Office, Royal Melbourne Hospital, 3050, Victoria, Australia
2 shared publicationsFrancesca Walker
The Cooperative Research Center for Cellular Growth Factors, Post Office Royal Melbourne Hospital, 3050, Victoria, Australia
1 shared publication- Suzanne Gaye Orchard
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
1 shared publication
Latest Publications
- 1 March 2003
- Published by Taylor & Francis in Growth Factors
- Vol. 21 (1) , 15-30
Epidermal Growth Factor Receptor: Association of Extracellular Domain Negatively Regulates Intracellular Kinase Activation in the Absence of Ligand
The epidermal growth factor receptor (EGFR) plays an important role in many types of human cancers. Receptor amplification, autocrine activation and/or deletion of exons 2–7 of EGFR gene have all been associated with tumor development. The traditional model of EGFR activation via ligand induced dimerization and consequential kinase activation does not provide full understanding of its tumorigenicity. The main function of the receptor extracellular domain (ECD) has been thought to be ligand recognition and binding. We report that the EGFR ECD, through its association also negatively regulates the activity of the intracellular kinase in the absence of ligand. Even in the absence of its ligands, the EGF receptor forms homodimers, however, the ECD prevents constitutive receptor kinase activation through its intrinsic ligand-independent interaction. The removal of this domain, either partial or total, results in constitutive activation of the receptor kinase as observed by its phosphorylation in intact cells. Furthermore, EGF receptors truncated in the ECD induce phosphorylation of the wild-type full-length receptor, indicating an inter-molecular inhibitory mechanism by the receptor ECD. The tumor associated Δ2–7EGFR mutant also dimerizes with and phosphorylates the wild type EGFR in the absence of ligand. Thus, in addition to its role in ligand recognition, EGFR ECD interacts with each other, imposing an inhibitory effect on the activation of the intracellular kinase.
- 1 March 2003
- Published by Taylor & Francis in Growth Factors
- Vol. 21 (1) , 15-30
Epidermal Growth Factor Receptor: Association of Extracellular Domain Negatively Regulates Intracellular Kinase Activation in the Absence of Ligand
The epidermal growth factor receptor (EGFR) plays an important role in many types of human cancers. Receptor amplification, autocrine activation and/or deletion of exons 2–7 of EGFR gene have all been associated with tumor development. The traditional model of EGFR activation via ligand induced dimerization and consequential kinase activation does not provide full understanding of its tumorigenicity. The main function of the receptor extracellular domain (ECD) has been thought to be ligand recognition and binding. We report that the EGFR ECD, through its association also negatively regulates the activity of the intracellular kinase in the absence of ligand. Even in the absence of its ligands, the EGF receptor forms homodimers, however, the ECD prevents constitutive receptor kinase activation through its intrinsic ligand-independent interaction. The removal of this domain, either partial or total, results in constitutive activation of the receptor kinase as observed by its phosphorylation in intact cells. Furthermore, EGF receptors truncated in the ECD induce phosphorylation of the wild-type full-length receptor, indicating an inter-molecular inhibitory mechanism by the receptor ECD. The tumor associated Δ2–7EGFR mutant also dimerizes with and phosphorylates the wild type EGFR in the absence of ligand. Thus, in addition to its role in ligand recognition, EGFR ECD interacts with each other, imposing an inhibitory effect on the activation of the intracellular kinase.
- 1 November 2001
- Published by Elsevier in Molecular Cell Biology Research Communications
- Vol. 4 (6) , 321-330
Regulation of Transforming Growth Factor-β Signaling
- 1 November 2001
- Published by Elsevier in Molecular Cell Biology Research Communications
- Vol. 4 (6) , 321-330
Regulation of Transforming Growth Factor-β Signaling
- Open Access
- 1 November 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (45) , 32258-32264
Smad7 Differentially Regulates Transforming Growth Factor β-mediated Signaling Pathways
- 1 November 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (45) , 32258-32264
Open AccessSmad7 Differentially Regulates Transforming Growth Factor β-mediated Signaling Pathways
- Open Access
- 1 October 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (41) , 29220-29227
Extracellular Domain of the Transforming Growth Factor-β Receptor Negatively Regulates Ligand-independent Receptor Activation
- 1 October 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (41) , 29220-29227
Open AccessExtracellular Domain of the Transforming Growth Factor-β Receptor Negatively Regulates Ligand-independent Receptor Activation